Every 8-K that Allarity Therapeutics, Inc. (ALLR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALLR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALLR filings page.
Allarity Therapeutics, Inc. (ALLR) disclosed that Allarity Acquisition Corp., a newly formed special purpose acquisition company sponsored by ALLR Sponsor LLC, has publicly filed a Form S-1 for a proposed Nasdaq-listed IPO of its units. The base offering size is expected to be $100 million, increasing to $115 million if the underwriters’ over-allotment option is exercised in full.
ALLR Sponsor LLC, a wholly owned subsidiary of Allarity, is expected to own about 25.0% of Allarity Acquisition Corp.’s issued and outstanding ordinary shares after the offering, as described in the S-1. The SPAC may pursue a business combination in any industry or region, and has applied to list its units on Nasdaq under the symbol ALLNU. Allarity stated that this SPAC initiative does not change its expectation that existing working capital can fund operations into the summer of 2028.
Allarity Therapeutics, Inc. reported second-quarter 2026 results and development progress for stenoparib, its dual PARP/tankyrase inhibitor for cancer. For the quarter ended June 30, 2026, the company generated no revenue and recorded a net loss of $3.4 million, compared with $2.3 million a year earlier, as other income swung to a net expense. Total operating expenses fell to $2.7 million from $4.1 million, reflecting lower research and development and general and administrative costs.
At June 30, 2026, Allarity held $17.0 million in cash and $10.0 million in restricted cash, with total assets of $32.1 million. Total liabilities rose to $28.6 million, driven largely by a new short-term promissory note of $20.9 million, reducing stockholders’ equity to $3.5 million. Operationally, the company completed a Phase 3-ready stenoparib manufacturing campaign, obtained CLIA certification for its in-house DRP companion diagnostic laboratory, and highlighted a newly granted U.S. patent extending stenoparib DRP exclusivity into 2042.
Allarity Therapeutics, Inc. reported results from its annual stockholder meeting and announced a newly granted U.S. patent. Stockholders elected Jesper Hoiland as director and ratified Wolf & Company, P.C. as auditor. They also approved an increase in shares available under the 2021 Equity Incentive Plan and an advisory vote on executive compensation.
Holders approved issuing common stock under a January 2026 Common Stock Purchase Agreement with Tumim Stone Capital LLC above the exchange cap, while an amendment to limit certain officer liability did not pass. Separately, the USPTO granted a key U.S. patent for Allarity’s stenoparib-specific DRP companion diagnostic, with a term extending into April 2042, supporting the company’s personalized oncology strategy.
Allarity Therapeutics, Inc. filed an 8-K to share a press release about presenting a Trial-in-Progress poster on its ongoing Phase 2 trial of stenoparib in advanced platinum-resistant or platinum-ineligible ovarian cancer at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen.
The poster explains the scientific background, study design, and clinical rationale, but does not include new clinical data. Allarity highlights prior Phase 2 experience showing durable clinical benefit in heavily pretreated ovarian cancer patients and its DRP® companion diagnostic strategy to select patients most likely to benefit from stenoparib.
Allarity Therapeutics, Inc. entered into an amended and restated Management Services Agreement with Ljungaskog Consulting AB, the firm of CEO Thomas H. Jensen, effective June 1, 2026. The agreement fully replaces the prior 2024 management services arrangement.
The consultant’s 2026 base compensation will be paid 80% in Swedish Krona and 20% in U.S. dollars, equal to SEK 6,000,000 and US$163,043. The prior one-time US$100,000 signing bonus is removed. Annual bonus metrics are to be set each year, with any bonus capped at 60% of fees paid and, if earned, payable by March 15 following year-end.
For a termination by the company for convenience, the notice period increases from 15 to 30 days and the consultant becomes eligible for a termination payment equal to 12 months of the monthly fee, in addition to accrued amounts, subject to conditions such as a release and cooperation. Upon a termination by the consultant for Good Reason, severance increases from nine months to 12 months of the monthly fee on similar conditions. The agreement also adds provisions addressing Sections 409A and 280G of the U.S. Internal Revenue Code when applicable.
Allarity Therapeutics, Inc. furnished an investor presentation and announced a speaking engagement by its CEO under a current report. The materials focus on stenoparib, an oral dual inhibitor of PARP and the WNT/tankyrase pathway, and the company’s Drug Response Predictor (DRP®) companion diagnostic platform.
The presentation highlights Phase 2 monotherapy data in heavily pretreated, platinum-resistant ovarian cancer, where stenoparib given twice daily showed a reported median overall survival of 22 months and extended benefit in patients with higher stenoparib-DRP scores. Allarity also describes ongoing Phase 2 trials in ovarian cancer and relapsed small cell lung cancer, and notes that its CEO will present “Dual Inhibition of PARP and WNT” at Precision Medicine Forum Europe 2026 in Stockholm.
Allarity Therapeutics, Inc. reports that its active pharmaceutical ingredient manufacturing campaign for stenoparib is progressing as planned, with completion expected no later than the third quarter of 2026 at a GMP-compliant contract manufacturer in Europe. This Phase 3-focused campaign is intended to secure drug supply to support a potential pivotal trial in advanced ovarian cancer following FDA Fast Track designation.
The company states that all manufacturing-related payments have been completed and that no additional cash outlays for this manufacturing campaign are anticipated. Ongoing Phase 2 trials in advanced ovarian cancer and relapsed small cell lung cancer continue to enroll patients, supported by Allarity’s DRP companion diagnostic approach.
Allarity Therapeutics, Inc. reported that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its patent application covering the DRP® companion diagnostic specific to its cancer drug candidate stenoparib. The patent is expected to be formally granted within three months, subject to standard administrative procedures, and would provide exclusivity at least into 2039 for stenoparib when used together with the DRP® test.
The allowed claims cover methods for predicting clinical benefit from stenoparib using gene expression profiles and selecting patients most likely to respond. Allarity already holds European and Australian patents for the Stenoparib DRP® and 18 granted patents for other drug-specific DRPs, including eight in the United States. The company continues Phase 2 development of stenoparib in ovarian cancer and small cell lung cancer while pursuing additional DRP® patent protection globally.
Allarity Therapeutics, Inc. filed a current report describing two new scientific posters on its lead drug candidate stenoparib and its DRP® companion diagnostic, presented at the AACR Annual Meeting 2026 in San Diego.
One poster links higher stenoparib DRP® scores with enhanced overall survival in a phase 2 trial in advanced, recurrent ovarian cancer, supporting DRP-based patient selection. The second poster shows stenoparib’s dual PARP/tankyrase mechanism can modulate the WNT/β-catenin signaling pathway and inhibit growth of colorectal cancer cell lines at clinically relevant concentrations.
The company emphasizes stenoparib’s potential in colorectal and ovarian cancers and highlights ongoing phase 2 trials in ovarian cancer and small cell lung cancer, alongside broader plans to use its DRP® platform to identify patients most likely to benefit from treatment.
Allarity Therapeutics reported 2025 results showing its first revenue and a sharply reduced loss as it advanced cancer drug stenoparib. Revenue reached $320 thousand from licensing agreements, compared to no revenue in 2024.
Net loss attributable to shareholders narrowed to $11.2 million, or $0.78 per share, versus $25.1 million, or $15.65 per share, reflecting lower operating costs. General and administrative expenses fell to $6.3 million from $11.4 million, while R&D rose modestly to $6.6 million. Cash was $14.7 million and total liabilities declined to $8.4 million as of December 31, 2025.
Allarity Therapeutics, Inc. announced it has closed a $20 million non-convertible debt financing with Streeterville Capital, structured via two promissory notes of $10,930,000 and $10,000,000, providing approximately $20 million in net proceeds.
The company expects this financing to extend its cash runway into the summer of 2028 and primarily use the funds to advance stenoparib in advanced ovarian cancer, including completing its Phase 2 trial, preparing for an FDA End-of-Phase-2 meeting, and supporting pivotal development and commercialization plans, as well as further developing its DRP companion diagnostic platform.
Allarity Therapeutics, Inc. entered into a financing arrangement with Streeterville Capital through two new promissory notes. The company issued an A-1 Note with an original principal amount of $10,930,000 and a secured B Note with an original principal amount of $10,000,000, both maturing 18 months after issuance.
After closing, Streeterville paid $10,000,000 to Allarity, and another $10,000,000 was placed in a controlled deposit account owned by a new wholly owned subsidiary, ALLR Holdings, LLC. The A-1 Note has a 9.00% annual interest rate and includes a $900,000 original issue discount and $30,000 of expenses, while the B Note bears 5.00% annual interest.
Beginning six months after issuance, the lender may redeem up to $250,000 plus accrued interest per month, payable in cash. The notes are secured by the controlled account, a guaranty from the subsidiary, and a pledge of all membership interests in the subsidiary, and include covenants restricting additional variable-price or secured financings and certain subsidiary activities. Trigger and default events can increase the outstanding balance and raise the interest rate up to 15% per year.
Allarity Therapeutics, Inc. announced that the first patients have been dosed with stenoparib in combination with temozolomide in a U.S. Department of Veterans Affairs–funded investigator-initiated Phase 2 trial for relapsed small cell lung cancer, an area described as having high unmet medical need.
The trial is fully funded through the VA’s Special Emphasis Panel on Precision Oncology and is open for enrollment across 11 VA medical centers in the United States. Allarity highlights stenoparib’s dual PARP and WNT pathway inhibition, its favorable safety profile compared with earlier PARP inhibitors, and its ability to cross the blood-brain barrier as potential advantages in this setting.
Allarity Therapeutics, Inc. reported that enrollment has opened for a new Phase 2 clinical trial. The study evaluates a combination of stenoparib and temozolomide to treat patients with recurrent small cell lung cancer.
The company released a press statement about this development, which is included as an exhibit to the report and incorporated by reference.
Allarity Therapeutics, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital, creating an equity line of credit that allows the company, at its sole discretion, to sell up to $6,000,000 of newly issued common shares over time.
Shares sold under the agreement will be priced at a discount to market, equal to either 95% of the lowest one-day volume‑weighted average price or 97% of the lowest three‑day volume‑weighted average price, subject to volume and dollar limits per draw of up to $1,000,000 or $2,000,000.
The investor cannot exceed 4.99% ownership of outstanding common stock, or 9.99% if it elects that higher cap. Issuances are also limited by an Exchange Cap tied to 19.99% of pre‑agreement shares outstanding, unless stockholders later approve a waiver and, if needed, an increase in authorized shares. Allarity paid a $45,000 commitment fee for this financing flexibility.
Allarity Therapeutics, Inc. reported that Dr. Jeremy Graff, its President and Chief Development Officer, presented new and updated clinical data from the company’s ongoing Phase 2 trial in advanced ovarian cancer. The presentation took place at the American Association for Cancer Research 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado.
The company also noted that a press release dated September 22, 2025, containing further details on the Phase 2 trial update has been issued and is included as an exhibit.
Allarity Therapeutics, Inc. filed a Form 8-K reporting a material event dated September 22, 2025. The filing lists two material agreements as exhibits: a Form of Securities Purchase Agreement and a Form of Registration Rights Agreement, each dated September 22, 2025, described as between the company and an investor. The document identifies the company's common stock ticker as ALLR on The Nasdaq Stock Market LLC and is signed by Thomas H. Jensen, Chief Executive Officer. The filing includes an Inline XBRL cover page reference but does not disclose financial terms, investor identity, or the size or economic impact of the transaction.
Allarity Therapeutics, Inc. reported that its CEO, Thomas Jensen, has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. The company also furnished a related press release as an exhibit, providing additional details on this conference participation.
Allarity Therapeutics, Inc. reported that the U.S. Food and Drug Administration has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer. The company disclosed that this development was announced in a press release dated August 26, 2025, which is included as an exhibit to the report.
On 15 Jul 2025 Allarity Therapeutics, Inc. (NASDAQ: ALLR) filed a Form 8-K under Item 8.01 to disclose the execution of a new commercial agreement with an undisclosed EU-based biotechnology company. The filing states only that the agreement was announced via a press release furnished as Exhibit 99.1, which is incorporated by reference.
No financial terms, partner identity, milestones, or projected revenue were provided in the 8-K, and the company did not report any changes to financial statements, guidance, or capital structure. Other 8-K items were not triggered. Investors must review Exhibit 99.1 for substantive economic details before assessing materiality.